Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

LAERDAL HEARTSTART SAFETY ALERT TO BE DISCUSSED BY FDA AND USERS

This article was originally published in The Gray Sheet

Executive Summary

LAERDAL HEARTSTART SAFETY ALERT TO BE DISCUSSED BY FDA AND USERS at a July 18 meeting, according to the American Heart Association. FDA called the invitation-only meeting after users expressed concerns about the appropriateness of recommendations made in a January FDA safety alert on Laerdal automatic external defibrillators.
Advertisement
Advertisement
UsernamePublicRestriction

Register

MT002556

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel